Overview
SCIENTIFIC SCORE
Questionable
Based on 18 Researches
6.7
USERS' SCORE
Good
Based on 8 Reviews
8.1
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin D3 (as Cholecalciferol) (From Lanolin)
1,250 mcg (50,000 IU)
6250%
Top Medical Research Studies
7
Vitamin D's role in heart health
We examined how low levels of vitamin D (Vit D) could impact the severity of heart disease, specifically looking at myocardial ischemia. Our study involved two hundred patients who underwent myocardial perfusion imaging at Namazi Hospital in Shiraz, Iran, in 2019. We assessed both the severity of ischemia in patients and their vitamin D levels.
The results revealed a clear pattern: when vitamin D levels dropped below 10 ng/mL, patients showed a significant increase in severe myocardial ischemia. Conversely, in patients with higher levels of vitamin D, we did not find any substantial association with abnormalities in heart imaging. This indicates that maintaining adequate vitamin D levels may play a role in reducing heart disease severity.
Overall, our findings suggest that vitamin D deficiency, especially levels below 10 ng/mL, could contribute to more severe heart conditions. This could prompt health care providers to consider monitoring and addressing vitamin D levels in patients at risk for heart disease.
The results revealed a clear pattern: when vitamin D levels dropped below 10 ng/mL, patients showed a significant increase in severe myocardial ischemia. Conversely, in patients with higher levels of vitamin D, we did not find any substantial association with abnormalities in heart imaging. This indicates that maintaining adequate vitamin D levels may play a role in reducing heart disease severity.
Overall, our findings suggest that vitamin D deficiency, especially levels below 10 ng/mL, could contribute to more severe heart conditions. This could prompt health care providers to consider monitoring and addressing vitamin D levels in patients at risk for heart disease.
Read More
8
We explored the relationship between vitamin D deficiency and heart disease, particularly how it interacts with a condition called hyperhomocysteinemia, which is known to promote heart issues. In our study, we examined both animal models (rats fed a diet to induce hyperhomocysteinemia) and heart cells under lab conditions to understand this interaction better.
Our findings revealed that hyperhomocysteinemia significantly lowered levels of vitamin D, specifically 1,25(OH)D, in the blood and heart tissues. We also noted an increase in the expression of an enzyme (CYP24A1) that breaks down vitamin D, indicating a disruption in its availability. Moreover, the presence of elevated homocysteine was linked to a decrease in vitamin D receptor (VDR) expression in heart tissues, complicating the heart's ability to respond to vitamin D’s effects.
By manipulating levels of VDR, we demonstrated that reducing VDR led to more heart cell growth, which is a sign of heart hypertrophy. Conversely, when VDR was overexpressed, we observed a decrease in hypertrophy, showing that vitamin D plays a protective role against heart enlargement during hyperhomocysteinemia. Additionally, a specific microRNA (miR-125b-5p) was found to repress VDR and contribute to heart cell growth, highlighting the complex regulatory network involved.
Our study concluded that vitamin D deficiency and reduced VDR contribute to heart issues associated with high levels of homocysteine by activating harmful cellular pathways. This underscores the potential significance of monitoring and supporting vitamin D levels, especially in individuals suffering from hyperhomocysteinemia.
Our findings revealed that hyperhomocysteinemia significantly lowered levels of vitamin D, specifically 1,25(OH)D, in the blood and heart tissues. We also noted an increase in the expression of an enzyme (CYP24A1) that breaks down vitamin D, indicating a disruption in its availability. Moreover, the presence of elevated homocysteine was linked to a decrease in vitamin D receptor (VDR) expression in heart tissues, complicating the heart's ability to respond to vitamin D’s effects.
By manipulating levels of VDR, we demonstrated that reducing VDR led to more heart cell growth, which is a sign of heart hypertrophy. Conversely, when VDR was overexpressed, we observed a decrease in hypertrophy, showing that vitamin D plays a protective role against heart enlargement during hyperhomocysteinemia. Additionally, a specific microRNA (miR-125b-5p) was found to repress VDR and contribute to heart cell growth, highlighting the complex regulatory network involved.
Our study concluded that vitamin D deficiency and reduced VDR contribute to heart issues associated with high levels of homocysteine by activating harmful cellular pathways. This underscores the potential significance of monitoring and supporting vitamin D levels, especially in individuals suffering from hyperhomocysteinemia.
Read More
8
Vitamin D improves heart health
We conducted a double-blind, randomized clinical trial to explore how treating vitamin D deficiency affects heart health, specifically in patients with ischemic heart disease (IHD). In our study, we involved 44 patients aged between 40 and 65 who were dealing with low vitamin D levels. They were divided into two groups—one receiving vitamin D supplements and the other a placebo.
Over five weeks, patients in the intervention group received weekly doses of 50,000 units of vitamin D. We measured changes in their lipid profiles, which includes important markers like cholesterol and triglycerides, as well as C-reactive protein (CRP), an indicator of inflammation.
Our findings revealed that vitamin D supplementation led to significant improvements. Patients in the intervention group showed an increase in good cholesterol (HDL) and a decrease in triglycerides, which are both beneficial for heart health. While the placebo group also experienced some minor improvements, the notable changes were primarily in the group receiving vitamin D.
Overall, these results suggest that addressing vitamin D deficiency can have positive effects on lipid levels in IHD patients. This is an encouraging insight for healthcare providers looking to manage heart disease risk more effectively.
Over five weeks, patients in the intervention group received weekly doses of 50,000 units of vitamin D. We measured changes in their lipid profiles, which includes important markers like cholesterol and triglycerides, as well as C-reactive protein (CRP), an indicator of inflammation.
Our findings revealed that vitamin D supplementation led to significant improvements. Patients in the intervention group showed an increase in good cholesterol (HDL) and a decrease in triglycerides, which are both beneficial for heart health. While the placebo group also experienced some minor improvements, the notable changes were primarily in the group receiving vitamin D.
Overall, these results suggest that addressing vitamin D deficiency can have positive effects on lipid levels in IHD patients. This is an encouraging insight for healthcare providers looking to manage heart disease risk more effectively.
Read More
Most Useful Reviews
9
Essential for bones
1 people found this helpful
This is a high-quality and easily absorbed product, vital for immune diseases and bone health. It greatly increases calcium absorption but should be taken with vitamin K2. I recommend larger packs for duration, since those with heart disease need adequate Vitamin D3 for sustained periods.
Read More
9
Medical supervision needed
For three years, I've followed a vitamin D protocol for my autoimmune condition, which had me on cortisone and strong medications. I now rely on this brand, which I believe is the best available, but it must be taken under medical supervision, particularly for heart disease.
Read More
7.5
Fewer flare-ups
2 people found this helpful
I genuinely feel the benefits of taking a high dose of Vitamin D. It is aiding my autoimmune diseases and I'm experiencing fewer flare-ups.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 18 Researches
6.7
- All Researches
8
We conducted a study to explore how vitamin D3, combined with SGLT2 inhibitors, could influence heart health in hypertensive obese patients suffering from obstructive sleep apnea (OSA). This combination therapy was assessed for its effects on various health parameters and the quality of life of the participants.
In our investigation, patients were randomly assigned to receive either Dapagliflozin, vitamin D3, a combination of both, or no treatment at all over 16 weeks. We closely looked at measurements such as weight, blood pressure, blood sugar levels, liver health, and heart function among others.
Our findings were promising, revealing beneficial effects of combining vitamin D3 with SGLT2 inhibitors. Participants who received this combination reported improvements in their cardio-metabolic health and overall quality of life, suggesting a potential new approach to managing heart disease in this specific group of patients.
It is important to note that while this study highlights the synergistic benefits of vitamin D3 and SGLT2 inhibitors, the isolated impact of vitamin D itself on heart disease remains somewhat unclear. This complexity underscores the need for further research to fully understand vitamin D's role in cardiovascular health.
In our investigation, patients were randomly assigned to receive either Dapagliflozin, vitamin D3, a combination of both, or no treatment at all over 16 weeks. We closely looked at measurements such as weight, blood pressure, blood sugar levels, liver health, and heart function among others.
Our findings were promising, revealing beneficial effects of combining vitamin D3 with SGLT2 inhibitors. Participants who received this combination reported improvements in their cardio-metabolic health and overall quality of life, suggesting a potential new approach to managing heart disease in this specific group of patients.
It is important to note that while this study highlights the synergistic benefits of vitamin D3 and SGLT2 inhibitors, the isolated impact of vitamin D itself on heart disease remains somewhat unclear. This complexity underscores the need for further research to fully understand vitamin D's role in cardiovascular health.
Read More
8
We explored the relationship between vitamin D deficiency and heart disease, particularly how it interacts with a condition called hyperhomocysteinemia, which is known to promote heart issues. In our study, we examined both animal models (rats fed a diet to induce hyperhomocysteinemia) and heart cells under lab conditions to understand this interaction better.
Our findings revealed that hyperhomocysteinemia significantly lowered levels of vitamin D, specifically 1,25(OH)D, in the blood and heart tissues. We also noted an increase in the expression of an enzyme (CYP24A1) that breaks down vitamin D, indicating a disruption in its availability. Moreover, the presence of elevated homocysteine was linked to a decrease in vitamin D receptor (VDR) expression in heart tissues, complicating the heart's ability to respond to vitamin D’s effects.
By manipulating levels of VDR, we demonstrated that reducing VDR led to more heart cell growth, which is a sign of heart hypertrophy. Conversely, when VDR was overexpressed, we observed a decrease in hypertrophy, showing that vitamin D plays a protective role against heart enlargement during hyperhomocysteinemia. Additionally, a specific microRNA (miR-125b-5p) was found to repress VDR and contribute to heart cell growth, highlighting the complex regulatory network involved.
Our study concluded that vitamin D deficiency and reduced VDR contribute to heart issues associated with high levels of homocysteine by activating harmful cellular pathways. This underscores the potential significance of monitoring and supporting vitamin D levels, especially in individuals suffering from hyperhomocysteinemia.
Our findings revealed that hyperhomocysteinemia significantly lowered levels of vitamin D, specifically 1,25(OH)D, in the blood and heart tissues. We also noted an increase in the expression of an enzyme (CYP24A1) that breaks down vitamin D, indicating a disruption in its availability. Moreover, the presence of elevated homocysteine was linked to a decrease in vitamin D receptor (VDR) expression in heart tissues, complicating the heart's ability to respond to vitamin D’s effects.
By manipulating levels of VDR, we demonstrated that reducing VDR led to more heart cell growth, which is a sign of heart hypertrophy. Conversely, when VDR was overexpressed, we observed a decrease in hypertrophy, showing that vitamin D plays a protective role against heart enlargement during hyperhomocysteinemia. Additionally, a specific microRNA (miR-125b-5p) was found to repress VDR and contribute to heart cell growth, highlighting the complex regulatory network involved.
Our study concluded that vitamin D deficiency and reduced VDR contribute to heart issues associated with high levels of homocysteine by activating harmful cellular pathways. This underscores the potential significance of monitoring and supporting vitamin D levels, especially in individuals suffering from hyperhomocysteinemia.
Read More
8
Vitamin D improves heart health
We conducted a double-blind, randomized clinical trial to explore how treating vitamin D deficiency affects heart health, specifically in patients with ischemic heart disease (IHD). In our study, we involved 44 patients aged between 40 and 65 who were dealing with low vitamin D levels. They were divided into two groups—one receiving vitamin D supplements and the other a placebo.
Over five weeks, patients in the intervention group received weekly doses of 50,000 units of vitamin D. We measured changes in their lipid profiles, which includes important markers like cholesterol and triglycerides, as well as C-reactive protein (CRP), an indicator of inflammation.
Our findings revealed that vitamin D supplementation led to significant improvements. Patients in the intervention group showed an increase in good cholesterol (HDL) and a decrease in triglycerides, which are both beneficial for heart health. While the placebo group also experienced some minor improvements, the notable changes were primarily in the group receiving vitamin D.
Overall, these results suggest that addressing vitamin D deficiency can have positive effects on lipid levels in IHD patients. This is an encouraging insight for healthcare providers looking to manage heart disease risk more effectively.
Over five weeks, patients in the intervention group received weekly doses of 50,000 units of vitamin D. We measured changes in their lipid profiles, which includes important markers like cholesterol and triglycerides, as well as C-reactive protein (CRP), an indicator of inflammation.
Our findings revealed that vitamin D supplementation led to significant improvements. Patients in the intervention group showed an increase in good cholesterol (HDL) and a decrease in triglycerides, which are both beneficial for heart health. While the placebo group also experienced some minor improvements, the notable changes were primarily in the group receiving vitamin D.
Overall, these results suggest that addressing vitamin D deficiency can have positive effects on lipid levels in IHD patients. This is an encouraging insight for healthcare providers looking to manage heart disease risk more effectively.
Read More
8
Vitamin D3 shows potential heart protection
We explored the effects of vitamin D3 and paricalcitol on heart health, particularly in the context of doxorubicin-induced cardiotoxicity. In our study, we worked with male Wistar rats divided into various groups, some receiving doxorubicin, a drug known for its heart-damaging potential. Others were treated with vitamin D3 or paricalcitol, both thought to have protective qualities against heart injury.
After administering doxorubicin, we observed significant changes in a range of biochemical markers and physiological indicators, including ECG readings and scintigraphy results. The findings suggested that both vitamin D3 and paricalcitol demonstrate potential cardioprotective effects by reducing inflammation and oxidative stress linked to heart damage.
This study shines a light on the possible benefits of vitamin D3 in protecting the heart during chemotherapy treatments. However, readers should note that while our findings are promising, they stem from an animal model, and further research is needed to confirm these effects in humans.
After administering doxorubicin, we observed significant changes in a range of biochemical markers and physiological indicators, including ECG readings and scintigraphy results. The findings suggested that both vitamin D3 and paricalcitol demonstrate potential cardioprotective effects by reducing inflammation and oxidative stress linked to heart damage.
This study shines a light on the possible benefits of vitamin D3 in protecting the heart during chemotherapy treatments. However, readers should note that while our findings are promising, they stem from an animal model, and further research is needed to confirm these effects in humans.
Read More
8
We examined how vitamin D3 could play a role in protecting the heart from damage caused by cisplatin, a chemotherapy drug. In our research, we worked with male Balb-c mice, dividing them into several groups to evaluate different treatment approaches. Some groups received vitamin D3 before or after cisplatin injection, while others acted as controls.
Our findings revealed that cisplatin significantly raised markers indicating heart damage and increased oxidative stress levels. In contrast, when we administered vitamin D3, whether as a preventive measure or treatment after cisplatin exposure, it showed promising results. It was able to improve heart tissue structure and biochemical indicators associated with heart injury, suggesting that vitamin D3 may mitigate some of the cardiac risks linked with chemotherapy.
However, while vitamin D3 showed a protective effect in the groups that received it before cisplatin treatment, the benefits were only partial when given afterward. This highlights the potential of vitamin D3 in supporting heart health during cancer treatment, although more research is necessary to understand its full capabilities and best applications.
Our findings revealed that cisplatin significantly raised markers indicating heart damage and increased oxidative stress levels. In contrast, when we administered vitamin D3, whether as a preventive measure or treatment after cisplatin exposure, it showed promising results. It was able to improve heart tissue structure and biochemical indicators associated with heart injury, suggesting that vitamin D3 may mitigate some of the cardiac risks linked with chemotherapy.
However, while vitamin D3 showed a protective effect in the groups that received it before cisplatin treatment, the benefits were only partial when given afterward. This highlights the potential of vitamin D3 in supporting heart health during cancer treatment, although more research is necessary to understand its full capabilities and best applications.
Read More
User Reviews
USERS' SCORE
Good
Based on 8 Reviews
8.1
- All Reviews
- Positive Reviews
- Negative Reviews
9
Essential for bones
1 people found this helpful
This is a high-quality and easily absorbed product, vital for immune diseases and bone health. It greatly increases calcium absorption but should be taken with vitamin K2. I recommend larger packs for duration, since those with heart disease need adequate Vitamin D3 for sustained periods.
Read More
9
Medical supervision needed
For three years, I've followed a vitamin D protocol for my autoimmune condition, which had me on cortisone and strong medications. I now rely on this brand, which I believe is the best available, but it must be taken under medical supervision, particularly for heart disease.
Read More
7.5
Fewer flare-ups
2 people found this helpful
I genuinely feel the benefits of taking a high dose of Vitamin D. It is aiding my autoimmune diseases and I'm experiencing fewer flare-ups.
Read More
7.5
Supports immunity
1 people found this helpful
Vitamin D³ is of excellent quality. Dr. Berg advises a dosage of 50,000 units once a week for average deficiencies, providing true support for immunity and overall health. I'm delighted with the quality and recommend it particularly to those with heart disease.
Read More
7.5
Severe deficiency improvement
1 people found this helpful
It’s crucial to analyse your vitamin D levels before taking it, especially with kidney disease. My doctor advised a strong weekly dose due to my severe deficiency. It’s excellent and significantly improves many aspects of my health, including my mood while helping with heart disease.
Read More
Frequently Asked Questions
7.5
Severe deficiency improvement
1 people found this helpful
It’s crucial to analyse your vitamin D levels before taking it, especially with kidney disease. My doctor advised a strong weekly dose due to my severe deficiency. It’s excellent and significantly improves many aspects of my health, including my mood while helping with heart disease.
7.5
Supports immunity
1 people found this helpful
Vitamin D³ is of excellent quality. Dr. Berg advises a dosage of 50,000 units once a week for average deficiencies, providing true support for immunity and overall health. I'm delighted with the quality and recommend it particularly to those with heart disease.
7.5
Fewer flare-ups
2 people found this helpful
I genuinely feel the benefits of taking a high dose of Vitamin D. It is aiding my autoimmune diseases and I'm experiencing fewer flare-ups.
7.5
Bone health enhancement
1 people found this helpful
One capsule of D3 50,000IU alongside MK7-K2 improves heart muscle and bone health, especially amidst a lack of sunlight. It’s beneficial to add calcium and magnesium, which is crucial for individuals with heart disease.
7.5
Regulates metabolism
1 people found this helpful
I take this once a week and am satisfied with the quality. Vitamin D provides numerous benefits, including metabolism regulation, heart health support, and immunity stimulation. It’s essential to take alongside fats in the morning and consult a doctor for the correct dosage.
9
Essential for bones
1 people found this helpful
This is a high-quality and easily absorbed product, vital for immune diseases and bone health. It greatly increases calcium absorption but should be taken with vitamin K2. I recommend larger packs for duration, since those with heart disease need adequate Vitamin D3 for sustained periods.
9
Medical supervision needed
For three years, I've followed a vitamin D protocol for my autoimmune condition, which had me on cortisone and strong medications. I now rely on this brand, which I believe is the best available, but it must be taken under medical supervision, particularly for heart disease.
7
Vitamin D's role in heart health
We examined how low levels of vitamin D (Vit D) could impact the severity of heart disease, specifically looking at myocardial ischemia. Our study involved two hundred patients who underwent myocardial perfusion imaging at Namazi Hospital in Shiraz, Iran, in 2019. We assessed both the severity of ischemia in patients and their vitamin D levels.
The results revealed a clear pattern: when vitamin D levels dropped below 10 ng/mL, patients showed a significant increase in severe myocardial ischemia. Conversely, in patients with higher levels of vitamin D, we did not find any substantial association with abnormalities in heart imaging. This indicates that maintaining adequate vitamin D levels may play a role in reducing heart disease severity.
Overall, our findings suggest that vitamin D deficiency, especially levels below 10 ng/mL, could contribute to more severe heart conditions. This could prompt health care providers to consider monitoring and addressing vitamin D levels in patients at risk for heart disease.
The results revealed a clear pattern: when vitamin D levels dropped below 10 ng/mL, patients showed a significant increase in severe myocardial ischemia. Conversely, in patients with higher levels of vitamin D, we did not find any substantial association with abnormalities in heart imaging. This indicates that maintaining adequate vitamin D levels may play a role in reducing heart disease severity.
Overall, our findings suggest that vitamin D deficiency, especially levels below 10 ng/mL, could contribute to more severe heart conditions. This could prompt health care providers to consider monitoring and addressing vitamin D levels in patients at risk for heart disease.
8
We conducted a study to explore how vitamin D3, combined with SGLT2 inhibitors, could influence heart health in hypertensive obese patients suffering from obstructive sleep apnea (OSA). This combination therapy was assessed for its effects on various health parameters and the quality of life of the participants.
In our investigation, patients were randomly assigned to receive either Dapagliflozin, vitamin D3, a combination of both, or no treatment at all over 16 weeks. We closely looked at measurements such as weight, blood pressure, blood sugar levels, liver health, and heart function among others.
Our findings were promising, revealing beneficial effects of combining vitamin D3 with SGLT2 inhibitors. Participants who received this combination reported improvements in their cardio-metabolic health and overall quality of life, suggesting a potential new approach to managing heart disease in this specific group of patients.
It is important to note that while this study highlights the synergistic benefits of vitamin D3 and SGLT2 inhibitors, the isolated impact of vitamin D itself on heart disease remains somewhat unclear. This complexity underscores the need for further research to fully understand vitamin D's role in cardiovascular health.
In our investigation, patients were randomly assigned to receive either Dapagliflozin, vitamin D3, a combination of both, or no treatment at all over 16 weeks. We closely looked at measurements such as weight, blood pressure, blood sugar levels, liver health, and heart function among others.
Our findings were promising, revealing beneficial effects of combining vitamin D3 with SGLT2 inhibitors. Participants who received this combination reported improvements in their cardio-metabolic health and overall quality of life, suggesting a potential new approach to managing heart disease in this specific group of patients.
It is important to note that while this study highlights the synergistic benefits of vitamin D3 and SGLT2 inhibitors, the isolated impact of vitamin D itself on heart disease remains somewhat unclear. This complexity underscores the need for further research to fully understand vitamin D's role in cardiovascular health.
5
We conducted a large-scale study to examine if giving older adults vitamin D on a monthly basis could help reduce major heart-related events like heart attacks and strokes. This randomized, double-blind trial involved over 21,000 participants aged 60 to 84 from Australia, who were assigned to either receive 60,000 IU of vitamin D or a placebo each month for up to five years.
During the study, we found that while there was a hint that vitamin D might lower the occurrence of these serious cardiovascular events, the differences observed were quite small. The confidence intervals surrounding these results suggest that they could just as easily represent no real effect at all.
It's important to note that we observed a significant number of participants successfully completing the study, with 80.2% taking vitamin D and 77.6% receiving the placebo. These findings lead us to believe that more detailed studies could be warranted to verify vitamin D's role, especially for people already using medications to prevent heart disease.
Overall, the evidence doesn't strongly support the idea that vitamin D supplements are a major game changer for heart health, but they may still have a role worth exploring further.
During the study, we found that while there was a hint that vitamin D might lower the occurrence of these serious cardiovascular events, the differences observed were quite small. The confidence intervals surrounding these results suggest that they could just as easily represent no real effect at all.
It's important to note that we observed a significant number of participants successfully completing the study, with 80.2% taking vitamin D and 77.6% receiving the placebo. These findings lead us to believe that more detailed studies could be warranted to verify vitamin D's role, especially for people already using medications to prevent heart disease.
Overall, the evidence doesn't strongly support the idea that vitamin D supplements are a major game changer for heart health, but they may still have a role worth exploring further.
8
Vitamin D improves heart health
We conducted a double-blind, randomized clinical trial to explore how treating vitamin D deficiency affects heart health, specifically in patients with ischemic heart disease (IHD). In our study, we involved 44 patients aged between 40 and 65 who were dealing with low vitamin D levels. They were divided into two groups—one receiving vitamin D supplements and the other a placebo.
Over five weeks, patients in the intervention group received weekly doses of 50,000 units of vitamin D. We measured changes in their lipid profiles, which includes important markers like cholesterol and triglycerides, as well as C-reactive protein (CRP), an indicator of inflammation.
Our findings revealed that vitamin D supplementation led to significant improvements. Patients in the intervention group showed an increase in good cholesterol (HDL) and a decrease in triglycerides, which are both beneficial for heart health. While the placebo group also experienced some minor improvements, the notable changes were primarily in the group receiving vitamin D.
Overall, these results suggest that addressing vitamin D deficiency can have positive effects on lipid levels in IHD patients. This is an encouraging insight for healthcare providers looking to manage heart disease risk more effectively.
Over five weeks, patients in the intervention group received weekly doses of 50,000 units of vitamin D. We measured changes in their lipid profiles, which includes important markers like cholesterol and triglycerides, as well as C-reactive protein (CRP), an indicator of inflammation.
Our findings revealed that vitamin D supplementation led to significant improvements. Patients in the intervention group showed an increase in good cholesterol (HDL) and a decrease in triglycerides, which are both beneficial for heart health. While the placebo group also experienced some minor improvements, the notable changes were primarily in the group receiving vitamin D.
Overall, these results suggest that addressing vitamin D deficiency can have positive effects on lipid levels in IHD patients. This is an encouraging insight for healthcare providers looking to manage heart disease risk more effectively.
References
- Vanreusel I, Hens W, Van Craenenbroeck EM, Paelinck BP, Segers VFM, et al. Vitamin D levels correlate with exercise capacity in adults with CHD. Cardiol Young. 2025. doi:10.1017/S1047951125000526
- Loh HH, Tay SP, Koa AJ, Yong MC, Said A, et al. Unveiling the benefits of Vitamin D3 with SGLT-2 inhibitors for hypertensive obese obstructive sleep apnea patients. J Transl Med. 2025;23:296. doi:10.1186/s12967-025-06312-w
- Qi H, Zhou Y, Hou HT, Wei JH, He GW, et al. Contributing role and molecular basis of Vitamin D/Vitamin D receptor deficiency in hyperhomocysteinemia-induced cardiac hypertrophy. Biochem Pharmacol. 2025;234:116812. doi:10.1016/j.bcp.2025.116812
- Haghighatafshar M, Shekasteband B, Firuzyar T, Etemadi Z, Farhoudi F, et al. The Impact of Vitamin D Deficiency on Coronary Artery Disease Severity Based on Myocardial Perfusion Imaging: A Cross-Sectional Study. Iran J Med Sci. 2025;50:31. doi:10.30476/ijms.2024.101112.3372
- Astani A, Maroofi A, Hekmatimoghaddam S, Sarebanhassanabadi M, Safari F. Sirtuin 1 mediates the pro-survival effects of vitamin D in angiotensin II-induced hypertrophy of H9c2 cardiomyoblasts. Mol Biol Rep. 2024;52:96. doi:10.1007/s11033-024-10168-6
- Algül E, Özbeyaz NB, Şahan HF, Aydinyilmaz F, Erdoğan A, et al. Low vitamin D levels are associated with impaired diastolic function in patients with acute coronary syndrome. Minerva Cardiol Angiol. 2025;73:57. doi:10.23736/S2724-5683.24.06515-3
- Sun L, Du J. Magnesium status, serum vitamin D concentration and mortality among congestive heart failure patients: a cohort study from NHANES 2007-2018. Magnes Res. 2024;37:61. doi:10.1684/mrh.2024.0528
- Aleksova A, Janjusevic M, Pani B, Hiche C, Chicco A, et al. The Co-Existence of Hypovitaminosis D and Diabetes Mellitus Triples the Incidence of Severe Coronary Artery Disease in Women. J Clin Med. 2024;13. doi:10.3390/jcm13226792
- Sadeghi M, Momeni A, Mirsaeidi FS, Jamalian M, Amirpour A, et al. The Effect of Vitamin D Deficiency Treatment on Lipid Profile and C-reactive Protein in Patients with Ischemic Heart Disease: Double-blind Randomized Clinical Trial. Adv Biomed Res. 2024;13:79. doi:10.4103/abr.abr_380_23
- Sato AY, Cregor M, McAndrews K, Schurman CA, Schaible E, et al. Pharmacologic or genetic interference with atrogene signaling protects against glucocorticoid-induced musculoskeletal and cardiac disease. JCI Insight. 2024;9. doi:10.1172/jci.insight.182664
- Stankiewicz B, Mieszkowski J, Kochanowicz A, Brzezińska P, Niespodziński B, et al. Effect of Single High-Dose Vitamin D Supplementation on Post-Ultra Mountain Running Heart Damage and Iron Metabolism Changes: A Double-Blind Randomized Controlled Trial. Nutrients. 2024;16. doi:10.3390/nu16152479
- Koroglu R, Koroglu M, Aygun H. Electrocardiographic, biochemical, and scintigraphic evidence for the cardioprotective effect of paricalcitol and vitamin D3 on doxorubicin-induced acute cardiotoxicity in rats. Bratisl Lek Listy. 2024;125:281. doi:10.4149/BLL_2024_42
- Hao N, Yong H, Zhang F, Liu C, Qiu Y, et al. Aortic calcification accelerates cardiac dysfunction via inducing apoptosis of cardiomyocytes. Int J Med Sci. 2024;21:306. doi:10.7150/ijms.90324
- Samavati I, Ranjbar A, Haddadi R. Cardioprotective effect of vitamin D3 on cisplatin-induced cardiotoxicity in male mice: role of oxidative stress. Naunyn Schmiedebergs Arch Pharmacol. 2024;397:4761. doi:10.1007/s00210-023-02848-0
- Ogata S, Manson JE, Kang JH, Buring JE, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes. Nutrients. 2023;15. doi:10.3390/nu15194235
- Arroyo E, Leber CA, Burney HN, Li Y, Li X, et al. Epimeric vitamin D and cardiovascular structure and function in advanced CKD and after kidney transplantation. Nephrol Dial Transplant. 2024;39:264. doi:10.1093/ndt/gfad168
- Hasific S, Øvrehus KA, Hosbond S, Lambrechtsen J, Kumarathurai P, et al. Effects of vitamins K2 and D3 supplementation in patients with severe coronary artery calcification: a study protocol for a randomised controlled trial. BMJ Open. 2023;13:e073233. doi:10.1136/bmjopen-2023-073233
- Thompson B, Waterhouse M, English DR, McLeod DS, Armstrong BK, et al. Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial. BMJ. 2023;381:e075230. doi:10.1136/bmj-2023-075230
